EP3116487A1 - Composition pharmaceutique de cinacalcet - Google Patents

Composition pharmaceutique de cinacalcet

Info

Publication number
EP3116487A1
EP3116487A1 EP14722332.5A EP14722332A EP3116487A1 EP 3116487 A1 EP3116487 A1 EP 3116487A1 EP 14722332 A EP14722332 A EP 14722332A EP 3116487 A1 EP3116487 A1 EP 3116487A1
Authority
EP
European Patent Office
Prior art keywords
weight
cinacalcet
composition according
composition
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP14722332.5A
Other languages
German (de)
English (en)
Inventor
Farhad Farshi
Udaya Kumar DUDE
Nadin Narsisoglu
Dr. Frank GINDULLIS
Didem YEGIN
Dr. Britta EVERS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karl O Helm AG
Abdi Ibrahim Ilac Sanayi Ve Ticaret AS
Original Assignee
Karl O Helm AG
Abdi Ibrahim Ilac Sanayi Ve Ticaret AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karl O Helm AG, Abdi Ibrahim Ilac Sanayi Ve Ticaret AS filed Critical Karl O Helm AG
Publication of EP3116487A1 publication Critical patent/EP3116487A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Definitions

  • the present invention is directed to a bioavailable and stable pharmaceutical composition
  • a bioavailable and stable pharmaceutical composition comprising cinacalcet or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, characterized in that the composition is prepared by wet granulation without binding agent.
  • Cinacalcet is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. Cinacalcet is described chemically as N-[l-(R)-(-)-(l- naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]-l-aminopropane and has the following structural formula:
  • Cinacalcet is commercially available in particular in hydrochloride salt form. Cinacalcet HC1 is a white to off-white, crystalline solid that is soluble in methanol or 95% ethanol and slightly soluble in water.
  • the commercial cinacalcet hydrochloride tablet formulation is marketed under the trade name Sensipar ® in the United States and Australia, and as Mimpara ® in Europe. These tablets are formulated as light-green, film-coated, oval-shaped tablets for oral administration in strengths of 30 mg, 60 mg, and 90 mg of cinacalcet HC1 as the free base equivalent (33 mg, 66 mg, and 99 mg as the hydrochloride salt, respectively).
  • Each tablet contains pregelatinized starch, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, and magnesium stearate. Tablets are coated with color (Opadry ® II green) and clear film-coat (Opadry ® clear), carnauba wax, and Opacode ® black ink.
  • Cinacalcet was first disclosed in the patent numbered EP0724561 by NPS Pharmaceuticals.
  • the patent also discloses usage of cinacalcet and its pharmaceutically acceptable salts, for treatment of primary or secondary hyperparathyroidism.
  • EP 1663182 discloses improving biovailability of cinacalcet hydrochloride by using from 45% to 85% by weight of at least one diluent and from 1% to 5% by weight of at least one binder in a composition. Further disclosed are compositions containing povidone as a binder and crospovidone as an excipient.
  • WO2011146583 describes a composition comprising nanoparticulate cinacalcet or a pharmaceutically acceptable salt thereof, and at least one surface stabilizer which is adsorbed onto or associated with the surface of the drug.
  • Exemplified are compositions containing Plasdone (PVP) as a surface stabilizer.
  • PVP Plasdone
  • EP2490674 relates to a tablet formulation comprising an intermediate which is obtained by the melt-extrusion of cinacalcet or a pharmaceutically acceptable salt thereof and matrix former.
  • Exemplified is a composition containing crospovidone as a disintegrant.
  • EP1945184 relates to a composition
  • a composition comprising solid composite of cinacalcet in intimate association with at least one carrier which is selected from the group consisting of povidone, poloxamer, hydroxypropyl methylcellulose, polyethylene glycol, copovidone, copolymers of methacrylate, copolymers of methacrylic acid, lower aliphatic alcohols and C3-C8 ketones.
  • EP 2334284 relates to an intermediate for preparation of a tablet, obtainable by jointly compacting crystalline cinacalcet with a hydrophilic polymer, such as PVP, a copolymer of vinyl pyrrolidone and vinyl acetate and/or PEG.
  • EP 2642980 discloses formulations comprising cinacalcet hydrochloride admixed with at least 2-5% w/w of silicon dioxide, in particular a powder formulation or pellets filled in a hard shell capsule.
  • the compositions disclosed also contain povidone.
  • the present invention is directed to a bioavailable and stable pharmaceutical composition
  • a bioavailable and stable pharmaceutical composition comprising cinacalcet or pharmaceutically acceptable salt thereof and at least one or more pharmaceutically acceptable excipients, characterized in that the composition is prepared by wet granulation without binding agent (s). It was surprisingly found that such a pharmaceutical composition is stable and can be prepared by a simple and cost effective process.
  • One object of the present invention is to provide a binder-free pharmaceutical composition of cinacalcet comprising pregelatinized starch in an amount from 0 % to 25 % by weight; preferably it is 5-15% by weight, and more preferably about 7 % by weight of the total pharmaceutical composition to achieve the desired dissolution profile.
  • Pregelatinized starch has the function of a disintegrant, as can be seen in Test Example 2.
  • Another object of the invention is to provide a pharmaceutical composition of cinacalcet which is free of povidone or crospovidone.
  • Cinacalcet compositions known in the the art like the tablets of the commercial product Mimpara ® contain polymer excipients based on pyrrole monomers, such as polyvinylpyrrolidone (PVP, povidone) or crospovidone. These excipients frequently contain peroxides and other secondary oxidation impurities, and it is known that reactive peroxides in povidone often lead to degradation of oxidation-labile drugs [Journal of Pharmaceutical Sciences 2012;101(l): 127-39] in the tablet. Stability studies of cinacalcet under various stress conditions revealed that this substance is especially sensitive towards peroxide oxidation, and degradation upon treatment with peroxides was observed (see Test Example 3).
  • cinacalcet compositions of the present invention are free of binding agents, in particular do not contain any povidone, the risk of degradation caused by peroxide impurities is reduced.
  • the presence of a binder in a formulation also requires the addition of (strong) disintegrants for a rapid dissolution.
  • the typical disintegrant used is crospovidone, which contributes to even higher levels of peroxide impurities.
  • a further object of the present invention is pharmaceutical compositions of cinacalcet which do not contain crospovidone as a disintegrant, thus reducing the risk of peroxide degradation (see Example 2).
  • Another object of the present invention is to provide a simple, cost-effective and time saving process for the preparation of solid composition of cinacalcet. It is known that binding agent is critical for attaining consistent granulation during the process of wet granulation. However, drying of wet granular mass containing binder agent(s) necessitates the utilization of higher temperatures for longer duration of time. Thus, exposure of the active ingredient to higher temperatures for longer duration may influence the impurity profile with respect to thermal and oxidative degradation of the active agent.
  • compositions manufactured without any binding agent(s) resulted in obtaining satisfactory results with respect to the manufacturing process (such as granulation, potency, flow attributes of granules and final blend including compression properties).
  • wet granulation is performed by adding pure water onto the dry blend of cinacalcet and excipients, thus avoiding the aforementioned agglomeration and sticking to the spray nozzles.
  • compositions manufactured without binding agent exhibit processing problems such as poor flowability, poor content uniformity, sticking and picking during the course of tablet compression.
  • lubricating agents such as magnesium stearate and stearic acid
  • utilization of higher levels of hydrophobic lubricating agents such as magnesium stearate in compositions containing hydrophobic actives such as cinacalcet HCI may prolong the disintegration time which in turn effects the dissolution behavior.
  • inventors of the present invention surprisingly found that the utilization of pregelatinized starch in an amount of 1 % to 25 % by weight and combination of talc and magnesium stearate in weight ratio between 1 :3 and 1 :0.1, preferably between 1 :2 and 1 :0.5, and more preferably of about 1 :0.5 (w/w) prevents these said problems and supports in achieving the desired pharmaceutical attributes such as disintegration time and dissolution behavior.
  • the main object of the present invention is to provide a binder-free pharmaceutical composition comprising cinacalcet and at least one or more pharmaceutically acceptable excipients.
  • Cinacalcet used throughout the text refers to cinacalcet or its pharmaceutically acceptable salt, solvate, polymorph, hydrate or enantiomer or a combination thereof.
  • cinacalcet is used in hydrochloride salt form in the formulations of the present invention.
  • composition may include other pharmaceutically acceptable excipients routinely used in the art of manufacturing pharmaceutical dosage forms.
  • pharmaceutically acceptable excipients include one or more fillers, disintegrants, lubricants, glidants, coloring agents, flavoring agents and coatings.
  • composition of the present invention is used by oral route.
  • Pharmaceutical composition to be used orally can be in the form of tablet (including film coated tablets, chewable tablets, effervescent tablets, layered tablet, soluble tablets, sublingual tablets, oral disintegrating tablets), capsule (including soft capsule and microcapsule), granules, grains, powders, pills, or combinations thereof.
  • the compositions of the present invention are preferably in tablet form and can optionally be film coated.
  • binder means a substance which is capable of facilitating granulation of the active agent into larger, denser, and more free -flowing particles, so it helps bind the active ingredient and other excipients together after compression.
  • binders include but are not limited to, polyvinylpyrrolidone (povidone, PVP), polyethylene glycol (PEG), cross-linked polyvinylpyrolidone, cellulose derivatives (such as hydroxymethyl cellulose, hydroxypropylcellulose, carboxy- methylcellulose sodium, ethyl cellulose, hydroxylethylcellose, hydroxypropylmethylcellulose), sucrose, alginic acid or sodium alginate, carbomer, cottonseed oil, dextrin, dextrose, guar gum, hydrogenated vegetable oil type I, magnesium aluminium silicate, maltodextrin, maltose, polydextrose, polyethylene oxide, stearic acid and zein.
  • the composition does not contain any binder agent; more specifically does not
  • the granulation solvent is selected from water and mixtures of aqueous and non-aqueous solvents such as ethanol, isopropanol alcohol and dichloromethane.
  • aqueous and non-aqueous solvents such as ethanol, isopropanol alcohol and dichloromethane.
  • disintegrant refers to any material that facilitates the break up of a tablet prepared from the composition when placed in contact with an aqueous medium.
  • Suitable disintegrants include, but are not limited to, crospovidone, sodium starch glycolate, hydroxypropyl starch, microcrystalline cellulose, carboxymethylcellulose sodium or calcium, croscarmellose, pregelatinized starch, polacrilin potassium, low-substituted hydroxypropylcellulose, sodium or calcium alginate, agar, guar gum, chitosan, alginic acid and mixtures thereof.
  • the composition preferably comprises from 2% to 10 % of disintegrant, in particular about 7 , based on the weight of the total composition.
  • 'filler' and the term 'diluent' are herein used interchangeably. It is known that, in general, the term 'filler' is used in the context of capsular formulations and the term 'diluent' in tablet formulations. Fillers fill out the size of a composition, making it practical to produce and convenient for the consumer to use. Suitable filler/diluent include, but are not limited to, calcium carbonate, calcium phosphate, dibasic calcium phosphate, tribasic calcium sulfate, calcium carboxymethylcellulose, cellulose, dextrin derivatives, dextrin, dextrose, fructose, lactitol, lactose (e.g.
  • methylcellulose polymers such as, e.g., Methocel A, Methocel A4C, Methocel A 15C, Metocel A4M), hydroxyethylcellulose, hydroxypropylcellulose, L-hydroxypropylycellulose (low substituted), hydroxypropyl methylcellulose (HPMC) (e.g.
  • Methocel E, F and K Metolose SH of Shin-Etsu, grades of Methocel F and Metolose 65 SH, the 4,000, 15,000 and 100,000 cps grades of Methocel K; and the 4,000, 15,000, 39,000 and 100,000 grades of Metolose 90 SH), sodium carboxymethylcellulose, carboxymethylene, carboxymethylhydroxyethylcellulose and other cellulose derivatives, starches or modified starches (including potato starch, wheat starch, corn starch, rice starch, pregelatinised maize starch), magnesium carbonate, magnesium oxide, maltitol, maltodextrins, maltose, sorbitol, starch, sucrose, sugar, and xylitol, erytritol.
  • the diluent/filler is lactose, microcrystalline cellulose or pregelatinized starch.
  • the amount of diluents used according to the present invention may be 20 to 95 w/w % , preferably about 50 to about 90 w/w % of a diluent, in particular about 60 to about 90 w/w % of a diluent, based on the total weight of the composition.
  • glidant as used in herein refers to any substance that is added to a powder to improve its flowability. Suitable glidants include, but are not limited, to at least one or a mixture of colloidal silicone dioxide, talc, aluminum silicate, magnesium silicate. Preferably the glidant is talc.
  • a lubricant is particularly preferred when the composition is a tablet as lubricants improve the tabletting process.
  • Lubricants prevent composition ingredients from clumping together and from sticking to the tablet punches or capsule filling machine and improve flowability of the composition mixture.
  • Suitable lubricants are preferably selected from stearic acid, stearic acid salts such as magnesium stearate, palmitic acid salts such as magnesium palmitate, oleic acid salts such as magnesium oleate, sodium lauryl sulfate, magnesium lauryl sulfate, hydrogenated vegetable oil, hydrogenated castor oil, talc, sodium stearyl fumarate, macrogols or mixtures thereof.
  • the lubricant is magnesium stearate.
  • the composition preferably comprises 0.5 to 5 wt % of lubricant.
  • Suitable coloring agents include one or more FDA approved colors for oral use.
  • the pharmaceutical formulations according to the present invention have the same dissolution profiles when compared to the reference product Mimpara ® , and especially have lower variability among different samples of a pharmaceutical formulation.
  • the variability of dissolution is measured using USP apparatus 2, placing each of the 6 formulation examples in 900 ml 0.05 N HCI at 37 ⁇ 0.5 °C with paddle speed of 75 rpm after 10, 15, 20, 30 and 45 minutes (see Fig. 1).
  • dissolution stability refers to the similarity of dissolution profiles (similarity factor greater than 50, in comparison to initial) obtained at different periods of storage at varying temperature and humidity conditions.
  • the term 'similarity factor' or '£2 factor' as used herein refers to one way of comparing dissolution profiles of two different products.
  • This model -independent mathematical approach compares the dissolution profile of the two products: test and reference or two strengths, or pre-and post-approved products from the same manufacturers. Tests are recommended to be performed under the same test conditions.
  • the dissolution time points for both the profiles should be the same, for example for immediate release products e.g. 10, 15, 20, 30, 45 minutes. Only one time point should be considered after 85% dissolution of any product.
  • An f2 value of 50 or greater (50-100) ensures sameness or equivalence of two curves, and thus performance of the two products.
  • the similarity factor f2 should be computed using the equation:
  • Rt and Tt are the cumulative percentage of the drug dissolved at each of the selected n time points of the comparison (reference) and (test) product respectively.
  • dissolution profiles may be accepted as similar without further mathematical evaluation.
  • Another object of the present invention is to provide a binder-free pharmaceutical composition of cinacalcet or pharmaceutically acceptable salt thereof, characterized in that the composition is comprising:
  • magnesium stearate as a lubricant, wherein the percentage by weight is relative to the total weight of the composition and wherein the composition does not contain povidone.
  • the disintegrant e.g. crospovidone or sodium starch glycolate
  • the weight ratio of disintegrant in intragranular part to extragranular part is 1:0.5 to 1 :3, preferably 1 :0.5 to achieve desired dissolution profile.
  • Another object of the invention is a method for preparing a pharmaceutical composition as disclosed above, comprising the steps of: a. Mixing cinacalcet hydrochloride, lactose monohydrate, microcrystalline cellulose, pregelatinized starch and crospovidone,
  • step b Drying and then sieving the wet granules obtained in step b;
  • step c Second part of microcrystalline cellulose and lactose monohydrate are weighed and mixed with granules obtained in step c;
  • step e Compressing the resulting mixture of step e into tablets.
  • the particle D 50 of the granules comprising cinacalcet hydrochloride is ranging from 100- 500 ⁇ , preferably from 200-350 ⁇ .
  • the particle size is determined by using Malvern Mastersizer analyzer or sieve analysis and it is important to achieve content uniformity and desired dissolution profile. Examples
  • compositions with targeted amounts of 30 mg, 60 mg and 90 mg active ingredient with the following components were prepared:
  • step (iii) Wet granules obtained in step (ii) are loaded into fluid-bed dryer and dried at 50-60 °C; iv. Sieving of dried granules; v. Second part of microcrystalline cellulose and lactose monohydrate are weighed and mixed with granules obtained in step iv;
  • step vi Talc and magnesium stearate are weighed and added into powders of step v, and mixed; vii. Powders of step vi are compressed using suitable punches;
  • Compressed tablets are coated with determined coating material.
  • Tablets were prepared by wet granulation process without binding agent(s) as same method described in the Example 1.
  • the dissolution profile of tablet is obtained according to Example 1 is tested by dissolution protocol described in USP 26/NF 21, chapter 711.
  • f2 value was found to be 96,4.
  • Test Example 2 Function study of pregelatinized starch
  • pregelatinized starch can be used as binder, disintegrant or diluent.
  • the dissolution test was performed to understand function of pregelatinized starch in present invention. For this purpose, dissolution profiles of Test example 2A (without pregelatinized starch), test example 2B (with 7% pregelatinized starch) and test example 2C (with 10% pregelatinized starch) and commercial reference product (Mimpara ® ) were compared. The dissolution tests were performed according to Test Example 1. Table 2: Test examples 1A, IB and 1C
  • Cinacalcet hydrochloride is especially sensitive to peroxide oxidation. For this reason, pharmaceutical expicients which contribute to peroxide content in the composition, such as povidone, were not used in the present invention to reduce peroxide degradation impurities.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition pharmaceutique biodisponible et stable comprenant du cinacalcet ou un sel pharmaceutiquement acceptable de celui-ci et un ou plusieurs excipients pharmaceutiquement acceptables. L'invention est caractérisée en ce que la composition est préparée par granulation par voie humide sans agent de liaison.
EP14722332.5A 2014-03-14 2014-03-14 Composition pharmaceutique de cinacalcet Pending EP3116487A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2014/059787 WO2015136329A1 (fr) 2014-03-14 2014-03-14 Composition pharmaceutique de cinacalcet

Publications (1)

Publication Number Publication Date
EP3116487A1 true EP3116487A1 (fr) 2017-01-18

Family

ID=50680077

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14722332.5A Pending EP3116487A1 (fr) 2014-03-14 2014-03-14 Composition pharmaceutique de cinacalcet

Country Status (2)

Country Link
EP (1) EP3116487A1 (fr)
WO (1) WO2015136329A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186516A1 (fr) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106692098B (zh) * 2016-12-30 2019-02-01 常州市阳光药业有限公司 盐酸西那卡塞速释制剂及其制备方法
EP3668493A4 (fr) * 2017-08-16 2021-08-25 Unichem Laboratories Ltd Compositions pharmaceutiques comprenant du chlorhydrate de cinacalcet et un ou plusieurs liants
CN109700778B (zh) * 2019-03-04 2021-08-13 南京恒生制药有限公司 一种盐酸西那卡塞速释制剂及其制备方法
CA3166210A1 (fr) * 2019-12-27 2021-07-01 Lupin Limited Composition pharmaceutique de modulateurs de casr et procedes et utilisations associes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1192011C (zh) 1991-08-23 2005-03-09 Nps药物有限公司 对钙受体具活性的芳烷基胺化合物
NZ545498A (en) 2003-09-12 2010-04-30 Amgen Inc Rapid dissolution formulation of a calcium receptor-active compound
JP5309014B2 (ja) * 2006-03-23 2013-10-09 アムジエン・インコーポレーテツド シナカルセットの多形体の製造および使用のための方法および組成物
CA2662315A1 (fr) 2006-09-01 2008-03-06 Teva Pharmaceutical Industries Ltd. Composites solides d'un compose actif vis-a-vis du recepteur calcique
WO2008064202A2 (fr) * 2006-11-20 2008-05-29 Dr. Reddy's Labortories, Ltd. Formulations à libération modifiée de composés actifs vis-à-vis du récepteur de calcium
EP2334284B1 (fr) 2008-09-25 2012-08-08 Ratiopharm GmbH Cinacalcet compacté
EP2314286A1 (fr) 2009-10-21 2011-04-27 Ratiopharm GmbH Cinacalcet en granulés à fondre
WO2011146583A2 (fr) 2010-05-19 2011-11-24 Elan Pharma International Limited Formulations de cinacalcet nanoparticulaire
WO2012071535A2 (fr) * 2010-11-23 2012-05-31 Amgen Inc Formulation pédiatrique
US20130085121A1 (en) * 2011-09-30 2013-04-04 Jianguo Wang Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
WO2013107503A1 (fr) * 2012-01-17 2013-07-25 Zentiva Saglik Urunleri San. Ve Tic. A.S. Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2015136329A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019186516A1 (fr) 2018-03-30 2019-10-03 Ftf Pharma Private Limited Formes posologiques liquides de cinacalcet ou d'un sel de celui-ci

Also Published As

Publication number Publication date
WO2015136329A1 (fr) 2015-09-17

Similar Documents

Publication Publication Date Title
JP4971159B2 (ja) プラミペキソール又はその薬学的に許容しうる塩を含有する徐放性ペレット製剤、その製法及び使用
CN106943355B (zh) 药物组合物
US20110300214A1 (en) Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid
EA025595B1 (ru) Фармацевтические композиции, содержащие 40-о-(2-гидрокси)этилрапамицин
EP3116487A1 (fr) Composition pharmaceutique de cinacalcet
AU2014295100B2 (en) Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
UA82597C2 (uk) Форма пролонгованого вивільнення гідрохлориду венлафаксину
EP2804588B1 (fr) Procédé de préparation de compositions de cinacalcet destinées à la fabrication directe de comprimés
WO2006123213A1 (fr) Preparations a liberation modifiee de gliclazide
WO2007049292A1 (fr) Formulation pharmaceutique de losartan
EP2155168A2 (fr) Nouvelles compositions stables de bisulfate de clopidogrel et leur procédé de préparation
WO2013008253A2 (fr) Formulations d'imatinib
WO2012139736A1 (fr) Composition pharmaceutique comprenant du bosentan
WO2010120963A1 (fr) Formulation de comprimé pour un inhibiteur de p38 et procédé
EP2503996A2 (fr) Compositions pharmaceutiques à libération contrôlée de galantamine
WO2014115082A1 (fr) Formulations pharmaceutiques d'imatinib
WO2017093890A1 (fr) Formulation de comprimé à base de clobazam et son procédé de préparation
WO2021106004A1 (fr) Composition pharmaceutique de s-adénosylméthionine
US20120121700A1 (en) Pharmaceutical formulations comprising valganciclovir
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
EP4279075A1 (fr) Composition pharmaceutique contenant de l'elagolix
EP3079672B1 (fr) Composition pharmaceutique comprenant un sel pharmaceutiquement acceptable de rasagiline
WO2023227997A1 (fr) Composition pharmaceutique contenant une combinaison d'azilsartan et de chlorthalidone et son procédé de préparation
KR20170029491A (ko) 제약 투여 형태
WO2022162687A1 (fr) Compositions pharmaceutiques comprenant du nilotinib

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20161014

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200429

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA